Dermata Therapeutics Inc (DRMA) Stock Price, Quote & News

Company Profile

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 800 2543

Website: www.dermatarx.com

Address:

3525 Del Mar Heights Rd., Suite 332, San Diego, United States

supplySHOCK Jun. 4 at 10:08 AM

$EDRY $DRMA $MOVE.X $BBGI normal

0 · Reply

supplySHOCK Jun. 3 at 9:02 PM

$INTG $GSIW $EDRY $DRMA digital

0 · Reply

HolEKa1010 Jun. 3 at 2:50 AM

$DRMA

0 · Reply

Buder Jun. 2 at 2:46 PM

$DRMA bullish

0 · Reply

MrTicker Jun. 1 at 8:37 PM

$DRMA Form SCHEDULE 13D Dermata Therapeutics, Filed by: Van Hoose Kyri K. 10K WIZARD 3:36 PM ET 6/1/2026 http://archive.fast-edgar.com/20260601/A322A22CZM2RJTQX222C2ZY2W6IHRZ22Z282 Filed on: June 1, 2026

0 · Reply

David_M_ May. 27 at 4:31 PM

$DRMA

0 · Reply

BillionaireMotion May. 21 at 10:58 PM

You miss all the insane 1,00%+ squeezers recently ??! Make sure ticker EZRA is on watch ! Starting to make a move now and breakout! Looks like shorts could get squeezed hard.. EZRA has 515k shares remaining to the public only . We saw a mini spike earlier.. Would not be shocked at all if it runs soon. Always try to buy early before the crowd does 🚀 💎 $AVCTQ $HOLO.X $JCSE $DRMA Small cap winner

0 · Reply

David_M_ May. 20 at 1:54 PM

$DRMA Ghost town here.

1 · Reply

David_M_ May. 17 at 2:33 AM

$DRMA https://ca.investing.com/news/stock-market-news/rbc-capital-initiates-dermata-therapeutics-stock-at-outperform-93CH-4584409

0 · Reply

brallt May. 14 at 12:20 PM

$DRMA Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 :: Dermata Therapeutics, Inc. (DRMA) https://share.google/5zgshp9gfaCI8wOWS

0 · Reply

Dermata Therapeutics Registration statement: Registration filing

May 13, 2026, 4:05 PM EDT - 22 days ago

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026

May 13, 2026, 8:00 AM EDT - 22 days ago

Dermata Therapeutics Quarterly report: Q1 2026

May 13, 2026, 8:00 AM EDT - 22 days ago

Dermata Therapeutics Earnings release: Q1 2026

Apr 17, 2026, 8:00 AM EDT - 6 weeks ago

Dermata Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 6 weeks ago

Dermata Therapeutics Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 2 months ago

Dermata Therapeutics Proxy statement: Proxy filing

2026-04-02T12:39:24.000Z - 2 months ago

Dermata receives notice of acceptance of Australian patent application

Apr 2, 2026, 8:30 AM EDT - 2 months ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

2026-04-01T12:35:12.000Z - 2 months ago

Dermata Therapeutics price target lowered to $4 from $10 at Maxim

Mar 26, 2026, 5:15 PM EDT - 2 months ago

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025

Mar 26, 2026, 8:00 AM EDT - 2 months ago

Dermata Therapeutics Annual report: Q4 2025

Mar 26, 2026, 8:00 AM EDT - 2 months ago

Dermata Therapeutics Earnings release: Q4 2025

2026-03-10T12:50:38.000Z - 3 months ago

Dermata Therapeutics appoints Kyra Peckaitis as VP, marketing

Mar 10, 2026, 8:30 AM EDT - 3 months ago

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

2026-03-05T14:07:31.000Z - 3 months ago

Dermata Therapeutics announces release of Tome Skincare

Mar 5, 2026, 9:00 AM EST - 3 months ago

Dermata Opens a New Chapter with the Release of Tome Skincare

2026-01-22T22:05:25.000Z - 4 months ago

Dermata Therapeutics files to sell 1.48M shares of common stock for holders

Jan 22, 2026, 7:00 AM EST - 4 months ago

Dermata Therapeutics Registration statement: Registration filing

2026-01-20T13:55:47.000Z - 4 months ago

Dermata Therapeutics receives notice of grant of patent for acne treatment

Jan 20, 2026, 8:05 AM EST - 4 months ago

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

Dec 29, 2025, 4:05 PM EST - 5 months ago

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

2025-12-24T13:15:17.000Z - 5 months ago

Dermata Therapeutics prices 2.02M shares at $2.04 in private placement

Dec 24, 2025, 8:00 AM EST - 5 months ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

2025-12-04T13:16:01.000Z - 6 months ago

Dermata Therapeutics to reveal brand name for OTC skincare business

Dec 4, 2025, 8:00 AM EST - 6 months ago

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

2025-11-24T16:35:08.000Z - 6 months ago

Dermata Therapeutics files $100M mixed securities shelf

Nov 24, 2025, 7:00 AM EST - 6 months ago

Dermata Therapeutics Registration statement: Registration filing

Nov 14, 2025, 4:05 PM EST - 7 months ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 7:00 AM EST - 7 months ago

Dermata Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 7 months ago

Dermata Therapeutics Earnings release: Q3 2025

2025-10-02T12:15:09.000Z - 8 months ago

Dermata says Australian Patent Office accepts Spongilla tech application

Oct 2, 2025, 8:00 AM EDT - 8 months ago

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Sep 17, 2025, 1:00 AM EDT - 9 months ago

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Sep 16, 2025, 8:35 AM EDT - 9 months ago

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

2025-09-10T12:20:14.000Z - 9 months ago

Dermata Therapeutics announces strategic pivot to OTC skin care treatments

2025-09-10T12:20:09.000Z - 9 months ago

Dermata Therapeutics withdraws IND application for XYNGARI

Sep 10, 2025, 8:00 AM EDT - 9 months ago

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

2025-08-21T13:00:32.000Z - 10 months ago

Dermata Therapeutics price target lowered to $10 from $30 at Maxim

Aug 13, 2025, 5:00 PM EDT - 10 months ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 8:00 AM EDT - 10 months ago

Dermata Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 10 months ago

Dermata Therapeutics Earnings release: Q2 2025

2025-07-31T23:50:23.000Z - 11 months ago

Dermata Therapeutics Inc trading halted, news pending

2025-07-08T12:50:59.000Z - 11 months ago

Dermata Therapeutics receives notice of grant of Australian patent

Jul 8, 2025, 8:00 AM EDT - 11 months ago

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Proxy statement: Proxy filing

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Proxy statement: Proxy filing

May 23, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Proxy statement: Proxy filing

2025-05-21T12:10:24.000Z - 1 year ago

Dermata Therapeutics price target lowered to $3 from $6 at Maxim

2025-05-14T13:25:20.000Z - 1 year ago

Dermata Therapeutics reports Q1 EPS (45c) vs. ($7.06) last year

2025-05-14T13:24:38.000Z - 1 year ago

Dermata Therapeutics sees cash runway into 1Q26

May 14, 2025, 9:00 AM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Earnings release: Q1 2025

2025-04-15T20:25:31.000Z - 1 year ago

Dermata Therapeutics files to sell 10.01M shares of common stock for holders

2025-04-15T13:36:04.000Z - 1 year ago

Dermata’s XYNGARI trial hits statistically significant difference at 4 weeks

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Registration statement: Registration filing

Mar 27, 2025, 8:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025, 9:57 AM EDT - 1 year ago

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Mar 27, 2025, 8:00 AM EDT - 1 year ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 17, 2025, 4:16 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Annual report: Q4 2024

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Earnings release: Q4 2024

Mar 4, 2025, 8:03 AM EST - 1 year ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Feb 25, 2025, 7:58 AM EST - 1 year ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jan 30, 2025, 7:00 AM EST - 1 year ago

Dermata Therapeutics Registration statement: Registration filing

Jan 29, 2025, 4:05 PM EST - 1 year ago

Dermata to Present on BioPub on January 31, 2025

Jan 28, 2025, 4:05 PM EST - 1 year ago

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Jan 23, 2025, 4:15 PM EST - 1 year ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025, 8:00 AM EST - 1 year ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 21, 2025, 8:00 AM EST - 1 year ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dec 16, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 10, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 3, 2024, 9:00 AM EST - 1 year ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 13, 2024, 4:15 PM EST - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 7:00 AM EST - 1 year ago

Dermata Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Dermata Therapeutics Earnings release: Q3 2024

Nov 11, 2024, 8:35 AM EST - 1 year ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Oct 8, 2024, 4:15 PM EDT - 1 year ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Registration statement: Registration filing

Sep 17, 2024, 5:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024, 9:00 PM EDT - 1 year ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Dermata Therapeutics Earnings release: Q2 2024

Jul 17, 2024, 9:00 AM EDT - 2 years ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Registration statement: Registration filing

May 17, 2024, 8:30 AM EDT - 2 years ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

May 15, 2024, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Quarterly report: Q1 2024

May 15, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Earnings release: Q1 2024

Mar 27, 2024, 4:05 PM EDT - 2 years ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Proxy statement: Proxy filing

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Proxy statement: Proxy filing

Mar 21, 2024, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Annual report: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Earnings release: Q4 2023

Mar 4, 2024, 7:00 AM EST - 2 years ago

Dermata Therapeutics Proxy statement: Proxy filing

Feb 1, 2024, 9:00 AM EST - 2 years ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Jan 4, 2024, 4:05 PM EST - 2 years ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Dec 20, 2023, 4:05 PM EST - 2 years ago

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dec 8, 2023, 7:00 AM EST - 2 years ago

Dermata Therapeutics Proxy statement: Proxy filing

Dec 7, 2023, 7:00 AM EST - 2 years ago

Dermata Therapeutics Registration statement: Registration filing

Nov 29, 2023, 7:00 AM EST - 2 years ago

Dermata Therapeutics Proxy statement: Proxy filing

Nov 16, 2023, 1:30 PM EST - 2 years ago

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 2 years ago

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Nov 9, 2023, 4:05 PM EST - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

supplySHOCK Jun. 4 at 10:08 AM

$EDRY $DRMA $MOVE.X $BBGI normal

0 · Reply

supplySHOCK Jun. 3 at 9:02 PM

$INTG $GSIW $EDRY $DRMA digital

0 · Reply

HolEKa1010 Jun. 3 at 2:50 AM

$DRMA

0 · Reply

Buder Jun. 2 at 2:46 PM

$DRMA bullish

0 · Reply

MrTicker Jun. 1 at 8:37 PM

0 · Reply

David_M_ May. 27 at 4:31 PM

$DRMA

0 · Reply

BillionaireMotion May. 21 at 10:58 PM

0 · Reply

David_M_ May. 20 at 1:54 PM

$DRMA Ghost town here.

1 · Reply

David_M_ May. 17 at 2:33 AM

$DRMA https://ca.investing.com/news/stock-market-news/rbc-capital-initiates-dermata-therapeutics-stock-at-outperform-93CH-4584409

0 · Reply

brallt May. 14 at 12:20 PM

$DRMA Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 :: Dermata Therapeutics, Inc. (DRMA) https://share.google/5zgshp9gfaCI8wOWS

0 · Reply

NotHopeJustFacts May. 12 at 2:55 PM

$BYND $AIXI sure, cause you're such a winner LMAO, it seems you do have a fetish for being a LOSER, POS like Beyond needs more bagholders like you, so bring your friends please so they can keep buying more of this Turd and maybe some more $DRMA LOL

0 · Reply

HolEKa1010 May. 8 at 7:02 PM

$DRMA

0 · Reply

brallt May. 1 at 2:48 PM

$DRMA Shorts have a strong interest in preventing 1.40-1.60+ price action to print on the daily. when zero sells are coming in around the 1mth high. within a building low volume uptrend off exausted sellers. Shorts pay a premium for sideways price action. (hopfully we can antaganize some shorts to provide us nice market buy adds)

0 · Reply